Literature DB >> 16495277

In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.

P J Yates1, R Hazen, M St Clair, L Boone, M Tisdale, R C Elston.   

Abstract

Development of in vitro resistance to GW640385, a new human immunodeficiency virus type 1 protease inhibitor, was studied. Variants characterized included one with <4-fold resistance and amino acid substitutions Q58E/A71V (protease) and P452K (Gag) and one with >50-fold resistance and amino acid substitutions L10F/G16E/E21K/A28S/M46I/F53L/A71V (protease) and L449F/P453T (Gag). The A28S substitution substantially reduced replication capacity.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16495277      PMCID： PMC1426426          DOI： 10.1128/AAC.50.3.1092-1095.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  HIV-1 integrase inhibition: binding sites, structure activity relationships and future perspectives.

Authors:  A L Parrill
Journal:  Curr Med Chem       Date:  2003-09       Impact factor: 4.530

2.  A rapid and simple colorimetric test for the study of anti-HIV agents.

Authors:  O Schwartz; Y Henin; V Marechal; L Montagnier
Journal:  AIDS Res Hum Retroviruses       Date:  1988-12       Impact factor: 2.205

3.  Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.

Authors:  D J Kempf; J D Isaacson; M S King; S C Brun; Y Xu; K Real; B M Bernstein; A J Japour; E Sun; R A Rode
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.

Authors:  Hiroyuki Gatanaga; Yasuhiro Suzuki; Hsinyi Tsang; Kazuhisa Yoshimura; Mark F Kavlick; Kunio Nagashima; Robert J Gorelick; Sek Mardy; Chun Tang; Michael F Summers; Hiroaki Mitsuya
Journal:  J Biol Chem       Date:  2001-12-10       Impact factor: 5.157

5.  Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Authors:  Thomas D Wu; Celia A Schiffer; Matthew J Gonzales; Jonathan Taylor; Rami Kantor; Sunwen Chou; Dennis Israelski; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

Authors:  Kazuhisa Yoshimura; Ryohei Kato; Mark F Kavlick; Aline Nguyen; Victor Maroun; Kenji Maeda; Khaja A Hussain; Arun K Ghosh; Sergei V Gulnik; John W Erickson; Hiroaki Mitsuya
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

Authors:  B A Larder; P Kellam; S D Kemp
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

8.  The prevalence of antiretroviral drug resistance in the United States.

Authors:  Douglas D Richman; Sally C Morton; Terri Wrin; Nicholas Hellmann; Sandra Berry; Martin F Shapiro; Samuel A Bozzette
Journal:  AIDS       Date:  2004-07-02       Impact factor: 4.177

9.  Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.

Authors:  Michael F Maguire; Rosario Guinea; Philip Griffin; Sarah Macmanus; Robert C Elston; Josie Wolfram; Naomi Richards; Mary H Hanlon; David J T Porter; Terri Wrin; Neil Parkin; Margaret Tisdale; Eric Furfine; Chris Petropoulos; B Wendy Snowden; Jörg-Peter Kleim
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Lay Myint; Masakazu Matsuda; Zene Matsuda; Yoshiyuki Yokomaku; Tomoko Chiba; Aiko Okano; Kaneo Yamada; Wataru Sugiura
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191
View more
  9 in total

1.  Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.

Authors:  Lucile Larrouy; C Chazallon; R Landman; C Capitant; G Peytavin; G Collin; C Charpentier; A Storto; G Pialoux; C Katlama; P M Girard; P Yeni; J P Aboulker; F Brun-Vezinet; D Descamps
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

2.  Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.

Authors:  Kazuhiko Ide; Manabu Aoki; Masayuki Amano; Yasuhiro Koh; Ravikiran S Yedidi; Debananda Das; Sofiya Leschenko; Bruno Chapsal; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.

Authors:  Yasuhiro Koh; Masayuki Amano; Tomomi Towata; Matthew Danish; Sofiya Leshchenko-Yashchuk; Debananda Das; Maki Nakayama; Yasushi Tojo; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

4.  A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance.

Authors:  Manabu Aoki; Simon B Chang; Debananda Das; Cuthbert Martyr; Nicole S Delino; Yuki Takamatsu; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Glob Health Med       Date:  2019-10-31

5.  Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance.

Authors:  Yuki Takamatsu; Manabu Aoki; Haydar Bulut; Debananda Das; Masayuki Amano; Venkata Reddy Sheri; Ladislau C Kovari; Hironori Hayashi; Nicole S Delino; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

6.  Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.

Authors:  Sarah K Ho; Roxana M Coman; Joshua C Bunger; Stephanie L Rose; Patricia O'Brien; Isabel Munoz; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  Virology       Date:  2008-07-02       Impact factor: 3.616

7.  In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.

Authors:  Richard Hazen; Robert Harvey; Robert Ferris; Charles Craig; Phillip Yates; Philip Griffin; John Miller; Istvan Kaldor; John Ray; Vincente Samano; Eric Furfine; Andrew Spaltenstein; Michael Hale; Roger Tung; Marty St Clair; Mary Hanlon; Lawrence Boone
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

8.  Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

Authors:  Francisco M Codoñer; Christian Pou; Alexander Thielen; Federico García; Rafael Delgado; David Dalmau; Miguel Álvarez-Tejado; Lidia Ruiz; Bonaventura Clotet; Roger Paredes
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

Review 9.  Human Immunodeficiency Virus Gag and protease: partners in resistance.

Authors:  Axel Fun; Annemarie M J Wensing; Jens Verheyen; Monique Nijhuis
Journal:  Retrovirology       Date:  2012-08-06       Impact factor: 4.602
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.